Dr. Elliott Sigal, a former director, executive vice president and chief scientific officer at Bristol-Myers Squibb Co (NYSE:BMY), is the newest director at the Philadelphia company. While at Bristol-Myers Squibb Co. (NYSE: BMY), Elliott is credited with leading the development of more than 14 new medicines approved to treat diseases such as cancer, mental illness and HIV/AIDS. Bristol-Myers Squibb Co (NYSE:BMY) stock opened at $52.62 in last session, and closed at $52.85, while the day range of BMY stock is $52.54 – $53.33. The stock showed a positive weekly performance of 8.88%.
Merck & Co., Inc. (NYSE:MRK) plan to sell its portfolio of popular consumer brands including Coppertone sun screen and Claritin allergy pills is kicking into high gear, with consumer and healthcare companies expected to put in bids that could top $10B. Merck & Co., Inc. (NYSE:MRK) stock opened at $55.44, in last session and closed at $55.00, by losing -1.26%. The 52 week range of MRK is $40.83 – $55.75. Company’s market capitalization is $160.96billion.
AbbVie Inc (NYSE:ABBV) is investing $230 million to set up a facility in Singapore; its first manufacturing plant in Asia. The facility will deal in production of immunology and oncology treatments. AbbVie Inc (NYSE:ABBV) stock advanced 1.81% and finished the last session at $50.56. The EPS of the stock remained 2.57. Company’s market capitalization is $80.28billion.
Pfizer Inc. (NYSE:PFE) and Science Foundation Ireland (SFI) have declared a partnership towards the development of treatments for rare diseases. Pfizer Inc. (NYSE:PFE) stock opened the session at $31.87, and closed the session at $31.61. The 52 week range of the PFE stock remained $26.81 – $32.50 and the day range was $31.55 – $32.00.